Kosheeka : Primary Cells for Research

  When it comes to understanding cancer, it is crucial to recognize the various types and their distinct characteristics. Two major categories of cancer that often arise in medical discussions are sarcoma and carcinoma. While both originate in different types of tissues, their progression, treatment options, and prognosis can significantly vary. In this blog, we will explore the origins of sarcoma and carcinoma and their unique progression patterns, and discuss how these differences impact their treatment approaches. Understanding Sarcoma Sarcoma is a type of cancer that develops from connective tissues, including bones, muscles, cartilage, blood vessels, and soft tissues. Unlike carcinoma, which typically originates from epithelial cells, sarcomas arise from mesenchymal cells . This distinction in tissue origin gives rise to notable differences in how sarcomas progress and spread. Origin and Progression of Sarcoma Sarcomas often begin in the supporting structures of the body, such as

The skin is one of the largest and most complex organs in the human body, and its function as a barrier to the external environment is critical for maintaining overall health and wellness. A key component of the skin is the dermis, a layer of tissue located beneath the epidermis that provides structural support and plays a critical role in wound healing and tissue repair. Dermal cells, specifically dermal fibroblasts and dermal macrophages are key components of the dermis and play important roles in maintaining skin health and function. Dermal fibroblasts are cells responsible for the production of extracellular matrix components such as collagen, elastin, and glycosaminoglycans. These components provide the structural support that gives the skin its strength and elasticity. Additionally, dermal fibroblasts play an important role in wound healing and tissue repair. Upon injury, dermal fibroblasts respond by proliferating and producing matrix components that help to close the wound and

The cluster of differentiation methodology used to identify cell surface antigens is where CD34 gets its name. Civin et al. and Tindle et al. simultaneously described CD34 for the first time on hematopoietic stem cells as a cell surface glycoprotein that serves as a cell-cell adhesion factor. Additionally, it might facilitate the bonding of hematopoietic stem cells with stromal cells or the extracellular matrix of bone marrow. In terms of medicine, it relates to the choice and enhancement of hematopoietic stem cells for bone marrow transplants. Although CD34 expression is actually seen on many other cell types, it is typically always associated with hematopoietic cells because of these historical and clinical links. Functions of CD 34 The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show the expression on early haematopoietic and vascular-associated progenitor cells. However, little is known about its exact function. CD34 is also an import

Animal use is required for preclinical investigations in life science research, which is time-consuming, costly, and causes animal cruelty. Animals being used in scientific research and tests has drawn criticism from environmentalists and animal rights activists. Several laws have also been proposed to restrict the use of animals in research. Researchers have been compelled by this to come up with alternatives that will promote compassion for animals while simultaneously reducing the number of animals exploited. In silico computer simulation and in vitro cell cultures are the two main substitutes for in vivo animal experimentation. Cell lines are now a simple tool to study nearly every subject connected to health and disease because of developments in cultural techniques. The ability to easily cultivate cells on dishes makes cell lines an effective tool for experimental studies. Cells can be easily cultivated in small containers at the workstation, and the number of cells can be simpl

  Cancer researchers can improve and hone cell and gene therapy choices to provide individualised medical treatments through the immunomodulatory properties of mesenchymal stem cells. Cancer medicine and therapy developers can alter the functioning of the cells to promote cancer suppression by utilising mesenchymal stem cells' capacity to modify the tumour microenvironment. Mesenchymal stem cells , for instance, present a route to deliver anti-cancer medications to tumour locations due to their propensity to move to tumours. Additionally, researchers can control mesenchymal stem cells via antibody treatment and modify the angiogenesis process, which cancers depend on to thrive. Immunomodulatory effects of MSCs The immunomodulatory characteristics of MSCs offer researchers a powerful weapon against cancer, serving as the foundation for immunotherapy . The development of immune system cells such macrophages, dendritic cells, T cells, B cells, and natural killer cells (NK cells), whi